uric acid has been researched along with Atrophy in 12 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
Atrophy: Decrease in the size of a cell, tissue, organ, or multiple organs, associated with a variety of pathological conditions such as abnormal cellular changes, ischemia, malnutrition, or hormonal changes.
Excerpt | Relevance | Reference |
---|---|---|
"We evaluated the association between baseline uric acid and the primary composite outcome of doubling of interstitium or ESRD from interstitial fibrosis and tubular atrophy (IF/TA) in the Angiotensin II Blockade for Chronic Allograft Nephropathy (ABCAN) Trial participants." | 9.19 | Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. ( Hart, A; Ibrahim, HN; Jackson, S; Kasiske, BL; Matas, AJ; Mauer, MS; Najafian, B; Spong, R, 2014) |
"Among patients with immunoglobulin A nephropathy, the higher levels of fibrinogen and uric acid may mean a higher score of tubular atrophy/interstitial fibrosis, which suggests the renal biopsy should be performed for these patients as early as possible to defined pathological classification, even though there is no obvious abnormal change in the test of renal function." | 8.12 | A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score. ( Hu, S; Lou, Z; Tu, M, 2022) |
"Renal handling of uric acid and clinical prognosis following episodes of macroscopic hematuria (EMH) were examined in 113 patients with IgA nephropathy (IgAN)." | 7.68 | Evidence of enhanced uric acid clearance in macrohematuric patients with IgA nephropathy: prognostic significance of macrohematuria. ( Miura, M; Nomoto, Y; Sakai, H, 1990) |
"We evaluated the association between baseline uric acid and the primary composite outcome of doubling of interstitium or ESRD from interstitial fibrosis and tubular atrophy (IF/TA) in the Angiotensin II Blockade for Chronic Allograft Nephropathy (ABCAN) Trial participants." | 5.19 | Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. ( Hart, A; Ibrahim, HN; Jackson, S; Kasiske, BL; Matas, AJ; Mauer, MS; Najafian, B; Spong, R, 2014) |
"Among patients with immunoglobulin A nephropathy, the higher levels of fibrinogen and uric acid may mean a higher score of tubular atrophy/interstitial fibrosis, which suggests the renal biopsy should be performed for these patients as early as possible to defined pathological classification, even though there is no obvious abnormal change in the test of renal function." | 4.12 | A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score. ( Hu, S; Lou, Z; Tu, M, 2022) |
" Blood urea nitrogen (BUN), serum creatinine (Scr), uric acid (UA) and proteinuria were evaluated." | 3.78 | Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model. ( He, J; Pei, X; Sun, S; Wang, C; Wang, Y; Wu, J; Yu, M; Zhao, W; Zhu, B, 2012) |
"Renal handling of uric acid and clinical prognosis following episodes of macroscopic hematuria (EMH) were examined in 113 patients with IgA nephropathy (IgAN)." | 3.68 | Evidence of enhanced uric acid clearance in macrohematuric patients with IgA nephropathy: prognostic significance of macrohematuria. ( Miura, M; Nomoto, Y; Sakai, H, 1990) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (50.00) | 18.7374 |
1990's | 1 (8.33) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 4 (33.33) | 24.3611 |
2020's | 1 (8.33) | 2.80 |
Authors | Studies |
---|---|
Tu, M | 1 |
Hu, S | 1 |
Lou, Z | 1 |
Zalewska, A | 1 |
Knaś, M | 1 |
Gińdzieńska-Sieśkiewicz, E | 1 |
Waszkiewicz, N | 1 |
Klimiuk, A | 1 |
Litwin, K | 1 |
Sierakowski, S | 1 |
Waszkiel, D | 1 |
Hart, A | 1 |
Jackson, S | 1 |
Kasiske, BL | 1 |
Mauer, MS | 1 |
Najafian, B | 1 |
Matas, AJ | 1 |
Spong, R | 1 |
Ibrahim, HN | 1 |
Ai, Z | 1 |
Xu, R | 1 |
Liu, W | 1 |
Zhou, Q | 1 |
Li, B | 1 |
Huang, F | 1 |
Yu, X | 1 |
Yang, Q | 1 |
He, J | 1 |
Wang, Y | 1 |
Sun, S | 1 |
Yu, M | 1 |
Wang, C | 1 |
Pei, X | 1 |
Zhu, B | 1 |
Wu, J | 1 |
Zhao, W | 1 |
Farstad, M | 1 |
Haug, JO | 1 |
Lindbak, H | 1 |
Skaug, OE | 1 |
VIVIER, G | 1 |
THOMAS, J | 1 |
Miura, M | 1 |
Nomoto, Y | 1 |
Sakai, H | 1 |
Passwell, J | 1 |
Zipperkowski, L | 1 |
Katznelson, D | 1 |
Szeinberg, A | 1 |
Crispin, M | 1 |
Pollak, S | 1 |
Goodman, R | 1 |
Bat-Miriam, M | 1 |
Cohen, BE | 1 |
Young, IJ | 1 |
Crampton, AR | 1 |
Shimizu, T | 1 |
Hiroata, R | 1 |
Nomura, Y | 1 |
Aibara, K | 1 |
Miyaki, K | 1 |
Simon, NM | 1 |
Smucker, JE | 1 |
O'Conor, VJ | 1 |
del Greco, F | 1 |
1 trial available for uric acid and Atrophy
Article | Year |
---|---|
Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial.
Topics: Allografts; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Atrophy; Biopsy; Chronic Diseas | 2014 |
11 other studies available for uric acid and Atrophy
Article | Year |
---|---|
A high value of fibrinogen in immunoglobulin A nephropathy patients is associated with a worse renal tubular atrophy/interstitial fibrosis score.
Topics: Adult; Atrophy; Female; Fibrinogen; Fibrosis; Glomerulonephritis, IGA; Humans; Kidney Tubules; Male; | 2022 |
Salivary antioxidants in patients with systemic sclerosis.
Topics: Adult; Aged; Antioxidants; Atrophy; Case-Control Studies; Colorimetry; DMF Index; Female; Fibrosis; | 2014 |
Clinicopathologic features of IgA nephropathy patients with different levels of proteinuria.
Topics: Adult; Atrophy; Biopsy; Female; Fibrosis; Glomerular Filtration Rate; Glomerulonephritis, IGA; Glome | 2016 |
Bone marrow stem cells-derived microvesicles protect against renal injury in the mouse remnant kidney model.
Topics: Animals; Atrophy; Biomarkers; Blood Urea Nitrogen; Bone Marrow Transplantation; Cell-Derived Micropa | 2012 |
URIC ACID IN THE CEREBROSPINAL FLUID IN CEREBRAL ATROPHY.
Topics: Atrophy; Blood Chemical Analysis; Brain Diseases; Cerebrospinal Fluid; Humans; Nervous System Diseas | 1965 |
[RENAL ATROPHIES OF URIC LITHIASIS. CIRCUMSTANCES OF APPEARANCE, EVOLUTION OF RADIOLOGICAL STUDY OF 5 CASES].
Topics: Atrophy; Humans; Kidney; Kidney Calculi; Kidney Diseases; Lithiasis; Pathology; Radiology; Uric Acid | 1965 |
Evidence of enhanced uric acid clearance in macrohematuric patients with IgA nephropathy: prognostic significance of macrohematuria.
Topics: Adult; Atrophy; Female; Follow-Up Studies; Glomerulonephritis, IGA; Hematuria; Humans; Kidney Functi | 1990 |
A syndrome characterized by congenital ichthyosis with atrophy, mental retardation, dwarfism, and generalized aminoaciduria.
Topics: Adolescent; Amino Acid Metabolism, Inborn Errors; Atrophy; Biopsy; Child; Consanguinity; Dermatoglyp | 1973 |
Cerebrospinal fluid uric acid levels in cerebral atrophy occurring in psychiatric and neurologic patients.
Topics: Adult; Age Factors; Aged; Alcoholism; Atrophy; Brain Diseases; Female; Hospitalization; Humans; Male | 1974 |
Nephrotoxic effect of MSG (monosodium glutamate) in the chicken.
Topics: Acute Kidney Injury; Animals; Atrophy; Body Weight; Chickens; Edema; Extremities; Gallbladder; Gluta | 1971 |
Differential uric acid excretion in essential and renal hypertension.
Topics: Atrophy; Glomerular Filtration Rate; Humans; Hydronephrosis; Hypertension; Hypertension, Renal; Kidn | 1969 |